Movalis (Meloxicam)

Meloxicam selectively blocks the cyclooxygenase‑2 (COX‑2) enzyme, which reduces the synthesis of prostaglandins—chemical mediators that cause inflammation, pain, and fever—thereby providing anti‑inflammatory and analgesic effects.

The appropriate dose of Movalis is determined by the prescribing clinician based on the patient’s condition, age, renal and hepatic function, and other individual factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Meloxicam is generally avoided in the third trimester of pregnancy because of potential risks to the fetus. Safety during breastfeeding has not been fully established, so clinicians usually recommend caution and evaluate the risk‑benefit ratio before use.

To order Movalis, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with non‑selective NSAIDs, meloxicam offers greater COX‑2 selectivity, which may lower the incidence of gastrointestinal irritation while still providing effective pain relief. However, cardiovascular and renal safety considerations remain similar to other NSAIDs and must be evaluated for each patient.

Store Movalis tablets at ambient temperature, preferably below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Movalis is taken orally, usually with a full glass of water. It may be taken with or without food, but taking it with food can help reduce occasional stomach discomfort. Patients should swallow the tablet whole and not split or crush it.

Serious risks include gastrointestinal ulceration or bleeding, severe liver injury, acute kidney failure, and cardiovascular events such as heart attack or stroke. Patients should seek immediate medical attention if they experience symptoms like severe abdominal pain, dark stools, jaundice, sudden swelling, or chest pain.

Movalis should be avoided in individuals with known hypersensitivity to meloxicam or other NSAIDs, those with active gastrointestinal ulcer disease, severe renal or hepatic impairment, uncontrolled hypertension, and in the third trimester of pregnancy. A healthcare professional should assess suitability before initiating therapy.